| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nitric Oxide | 88 | 2023 | 881 | 7.710 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 26 | 2024 | 203 | 6.370 |
Why?
|
| Persistent Fetal Circulation Syndrome | 37 | 2023 | 136 | 5.110 |
Why?
|
| Hypertension, Pulmonary | 45 | 2023 | 1749 | 3.540 |
Why?
|
| Respiratory Insufficiency | 29 | 2023 | 311 | 3.500 |
Why?
|
| Extracorporeal Membrane Oxygenation | 30 | 2024 | 281 | 3.330 |
Why?
|
| Bronchopulmonary Dysplasia | 18 | 2024 | 377 | 2.620 |
Why?
|
| Administration, Inhalation | 70 | 2023 | 661 | 2.480 |
Why?
|
| Infant, Newborn | 106 | 2024 | 5740 | 2.270 |
Why?
|
| Infant, Premature | 31 | 2024 | 538 | 1.920 |
Why?
|
| Hemodynamics | 40 | 2022 | 1077 | 1.820 |
Why?
|
| High-Frequency Ventilation | 20 | 2006 | 45 | 1.810 |
Why?
|
| Bronchodilator Agents | 12 | 2020 | 243 | 1.780 |
Why?
|
| Vasodilator Agents | 15 | 2022 | 324 | 1.680 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 13 | 2011 | 101 | 1.680 |
Why?
|
| Oxygen Inhalation Therapy | 10 | 2015 | 141 | 1.630 |
Why?
|
| Pulmonary Circulation | 31 | 2006 | 417 | 1.430 |
Why?
|
| Hernia, Diaphragmatic | 9 | 2021 | 69 | 1.400 |
Why?
|
| Infant, Premature, Diseases | 6 | 2019 | 93 | 1.300 |
Why?
|
| Ventricular Dysfunction, Left | 4 | 2022 | 383 | 1.240 |
Why?
|
| Respiration, Artificial | 25 | 2019 | 604 | 1.110 |
Why?
|
| Hypoxia | 19 | 2021 | 1035 | 1.060 |
Why?
|
| Oxygen | 21 | 2021 | 901 | 0.990 |
Why?
|
| Vascular Resistance | 29 | 2021 | 367 | 0.940 |
Why?
|
| Echocardiography | 13 | 2023 | 624 | 0.890 |
Why?
|
| Blood Gas Analysis | 7 | 2021 | 71 | 0.850 |
Why?
|
| Lung | 33 | 2023 | 3748 | 0.850 |
Why?
|
| Humans | 165 | 2024 | 128499 | 0.840 |
Why?
|
| Gestational Age | 22 | 2024 | 871 | 0.830 |
Why?
|
| Transportation of Patients | 3 | 2020 | 50 | 0.810 |
Why?
|
| Propofol | 5 | 2024 | 52 | 0.770 |
Why?
|
| Bronchoconstriction | 1 | 2020 | 32 | 0.690 |
Why?
|
| Sheep | 40 | 2007 | 831 | 0.660 |
Why?
|
| Ventricular Dysfunction | 1 | 2019 | 15 | 0.660 |
Why?
|
| Pulmonary Gas Exchange | 11 | 2009 | 118 | 0.650 |
Why?
|
| Critical Care | 6 | 2013 | 551 | 0.640 |
Why?
|
| Pre-Eclampsia | 2 | 2024 | 185 | 0.630 |
Why?
|
| Heart Atria | 1 | 2020 | 128 | 0.630 |
Why?
|
| Anaphylaxis | 1 | 2020 | 98 | 0.630 |
Why?
|
| Vasodilation | 20 | 2005 | 461 | 0.630 |
Why?
|
| Fetus | 21 | 2018 | 765 | 0.630 |
Why?
|
| Cardiovascular System | 1 | 2020 | 137 | 0.610 |
Why?
|
| Ductus Arteriosus, Patent | 4 | 2015 | 49 | 0.610 |
Why?
|
| Infant | 35 | 2024 | 9001 | 0.610 |
Why?
|
| Trachea | 2 | 2018 | 221 | 0.560 |
Why?
|
| Heart Ventricles | 3 | 2020 | 767 | 0.550 |
Why?
|
| Early Medical Intervention | 2 | 2014 | 57 | 0.540 |
Why?
|
| Anesthetics, Intravenous | 4 | 2024 | 38 | 0.540 |
Why?
|
| Pulmonary Surfactants | 6 | 2021 | 105 | 0.530 |
Why?
|
| Animals, Newborn | 18 | 2007 | 808 | 0.530 |
Why?
|
| Monitoring, Physiologic | 3 | 2019 | 264 | 0.510 |
Why?
|
| Prenatal Diagnosis | 1 | 2018 | 190 | 0.510 |
Why?
|
| Endothelium-Dependent Relaxing Factors | 1 | 2015 | 16 | 0.510 |
Why?
|
| Hyaline Membrane Disease | 6 | 1998 | 20 | 0.500 |
Why?
|
| Blood Coagulation | 1 | 2017 | 236 | 0.500 |
Why?
|
| Severity of Illness Index | 13 | 2024 | 2719 | 0.500 |
Why?
|
| Pulmonary Artery | 20 | 2021 | 1031 | 0.490 |
Why?
|
| Intensive Care Units | 4 | 2018 | 735 | 0.490 |
Why?
|
| Umbilical Arteries | 1 | 2015 | 51 | 0.480 |
Why?
|
| Radial Artery | 1 | 2015 | 69 | 0.480 |
Why?
|
| Female | 76 | 2024 | 68268 | 0.460 |
Why?
|
| Vitamin A | 1 | 2013 | 55 | 0.430 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 1490 | 0.430 |
Why?
|
| Oxygen Consumption | 3 | 2015 | 671 | 0.420 |
Why?
|
| Superoxide Dismutase | 2 | 2006 | 337 | 0.420 |
Why?
|
| Male | 59 | 2024 | 63045 | 0.410 |
Why?
|
| Conscious Sedation | 2 | 2010 | 84 | 0.400 |
Why?
|
| Vitamins | 1 | 2013 | 174 | 0.400 |
Why?
|
| Hospital Mortality | 4 | 2018 | 847 | 0.380 |
Why?
|
| Retrospective Studies | 26 | 2024 | 14472 | 0.380 |
Why?
|
| Intestinal Obstruction | 1 | 2012 | 49 | 0.380 |
Why?
|
| Phosphodiesterase Inhibitors | 5 | 2013 | 85 | 0.370 |
Why?
|
| Alcohol-Related Disorders | 1 | 2013 | 118 | 0.370 |
Why?
|
| Anesthesia, General | 2 | 2005 | 49 | 0.370 |
Why?
|
| Muscle, Smooth, Vascular | 8 | 2005 | 418 | 0.370 |
Why?
|
| Lung Diseases | 6 | 2010 | 715 | 0.350 |
Why?
|
| Paresis | 1 | 2010 | 30 | 0.340 |
Why?
|
| Emergency Medicine | 1 | 2013 | 215 | 0.340 |
Why?
|
| Sulfones | 4 | 2013 | 108 | 0.330 |
Why?
|
| Dietary Supplements | 1 | 2013 | 531 | 0.320 |
Why?
|
| Adrenal Insufficiency | 1 | 2010 | 32 | 0.320 |
Why?
|
| Treatment Outcome | 25 | 2024 | 10162 | 0.320 |
Why?
|
| Nitric Oxide Synthase | 15 | 2005 | 230 | 0.320 |
Why?
|
| Survival Rate | 14 | 2022 | 1871 | 0.320 |
Why?
|
| Dipyridamole | 6 | 1998 | 25 | 0.310 |
Why?
|
| Herniorrhaphy | 2 | 2020 | 57 | 0.310 |
Why?
|
| Pacemaker, Artificial | 1 | 2009 | 110 | 0.300 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2010 | 190 | 0.300 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2011 | 223 | 0.300 |
Why?
|
| Nose | 2 | 2008 | 64 | 0.300 |
Why?
|
| Heart Defects, Congenital | 7 | 2022 | 750 | 0.290 |
Why?
|
| Meconium Aspiration Syndrome | 3 | 2003 | 11 | 0.290 |
Why?
|
| Fluorocarbons | 2 | 1999 | 109 | 0.280 |
Why?
|
| Cardiac Output | 8 | 2009 | 154 | 0.270 |
Why?
|
| Anticoagulants | 2 | 2024 | 634 | 0.270 |
Why?
|
| Foreign Bodies | 1 | 2008 | 101 | 0.270 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 3387 | 0.270 |
Why?
|
| Action Potentials | 1 | 2010 | 469 | 0.270 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2007 | 130 | 0.270 |
Why?
|
| Pregnancy | 19 | 2024 | 6373 | 0.260 |
Why?
|
| Animals | 60 | 2022 | 34647 | 0.260 |
Why?
|
| Thyroidectomy | 2 | 2024 | 86 | 0.250 |
Why?
|
| Child | 21 | 2022 | 20805 | 0.250 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2013 | 953 | 0.240 |
Why?
|
| Piperazines | 3 | 2013 | 333 | 0.240 |
Why?
|
| Respiration Disorders | 1 | 2005 | 72 | 0.230 |
Why?
|
| Hirudins | 1 | 2024 | 52 | 0.230 |
Why?
|
| Neck Pain | 1 | 2024 | 26 | 0.230 |
Why?
|
| Respiration | 3 | 2019 | 190 | 0.230 |
Why?
|
| Muscle Stretching Exercises | 1 | 2024 | 18 | 0.230 |
Why?
|
| Antithrombins | 1 | 2024 | 58 | 0.230 |
Why?
|
| Tracheostomy | 2 | 2024 | 120 | 0.230 |
Why?
|
| Preoperative Care | 3 | 2017 | 336 | 0.220 |
Why?
|
| Postoperative Hemorrhage | 1 | 2024 | 87 | 0.220 |
Why?
|
| Ventricular Function, Left | 6 | 2020 | 524 | 0.210 |
Why?
|
| Heart | 3 | 2019 | 637 | 0.210 |
Why?
|
| Pulmonary Alveoli | 3 | 2021 | 365 | 0.210 |
Why?
|
| Ductus Arteriosus | 11 | 2005 | 71 | 0.210 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2020 | 1951 | 0.210 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2024 | 68 | 0.210 |
Why?
|
| Heparin | 1 | 2024 | 253 | 0.210 |
Why?
|
| Fatal Outcome | 4 | 2012 | 301 | 0.200 |
Why?
|
| Nitrites | 1 | 2002 | 81 | 0.200 |
Why?
|
| Antioxidants | 1 | 2006 | 545 | 0.200 |
Why?
|
| Infant, Very Low Birth Weight | 2 | 2017 | 67 | 0.200 |
Why?
|
| Gastroesophageal Reflux | 2 | 2022 | 230 | 0.200 |
Why?
|
| Respiratory Therapy | 3 | 2003 | 23 | 0.190 |
Why?
|
| Incidence | 5 | 2015 | 2638 | 0.190 |
Why?
|
| Prospective Studies | 10 | 2023 | 7069 | 0.190 |
Why?
|
| Precision Medicine | 2 | 2023 | 386 | 0.180 |
Why?
|
| Risk Factors | 11 | 2024 | 9737 | 0.180 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2001 | 40 | 0.180 |
Why?
|
| Vasoconstriction | 3 | 2005 | 185 | 0.180 |
Why?
|
| Emergency Treatment | 1 | 2002 | 113 | 0.180 |
Why?
|
| Neuromuscular Nondepolarizing Agents | 1 | 2020 | 13 | 0.180 |
Why?
|
| Plethysmography | 1 | 2001 | 107 | 0.170 |
Why?
|
| Peptide Fragments | 1 | 2024 | 688 | 0.170 |
Why?
|
| Respiratory Function Tests | 5 | 2019 | 580 | 0.170 |
Why?
|
| Fundoplication | 1 | 2020 | 54 | 0.170 |
Why?
|
| Postoperative Complications | 6 | 2017 | 2462 | 0.170 |
Why?
|
| Papio | 6 | 1995 | 91 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2019 | 1358 | 0.170 |
Why?
|
| Carbon Monoxide | 1 | 2000 | 68 | 0.170 |
Why?
|
| Time Factors | 12 | 2017 | 6506 | 0.170 |
Why?
|
| Fluid Therapy | 2 | 2011 | 134 | 0.170 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2020 | 60 | 0.170 |
Why?
|
| Blood Pressure | 13 | 2014 | 1712 | 0.160 |
Why?
|
| Patient Care Team | 2 | 2016 | 598 | 0.160 |
Why?
|
| Pulmonary Veins | 2 | 1999 | 93 | 0.160 |
Why?
|
| Infusions, Intravenous | 4 | 2024 | 394 | 0.160 |
Why?
|
| Thrombelastography | 1 | 2020 | 150 | 0.160 |
Why?
|
| Neoplasm Staging | 3 | 2018 | 1292 | 0.160 |
Why?
|
| Combined Modality Therapy | 7 | 2017 | 1201 | 0.150 |
Why?
|
| Critical Illness | 3 | 2014 | 755 | 0.150 |
Why?
|
| Blood Coagulation Disorders | 1 | 2020 | 167 | 0.150 |
Why?
|
| Treatment Failure | 5 | 2007 | 338 | 0.150 |
Why?
|
| Risk | 3 | 2021 | 853 | 0.150 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2018 | 71 | 0.140 |
Why?
|
| Single-Blind Method | 2 | 2013 | 268 | 0.140 |
Why?
|
| Cerebral Hemorrhage | 2 | 2014 | 106 | 0.140 |
Why?
|
| Intubation, Intratracheal | 2 | 2018 | 238 | 0.140 |
Why?
|
| Abnormalities, Multiple | 1 | 2019 | 178 | 0.140 |
Why?
|
| Retinopathy of Prematurity | 1 | 2019 | 138 | 0.140 |
Why?
|
| Heart Rate | 4 | 2009 | 798 | 0.140 |
Why?
|
| Pneumonectomy | 1 | 2019 | 151 | 0.140 |
Why?
|
| Thiopental | 1 | 1997 | 3 | 0.140 |
Why?
|
| Ondansetron | 1 | 1997 | 15 | 0.140 |
Why?
|
| Biological Products | 1 | 2000 | 199 | 0.140 |
Why?
|
| Emergency Service, Hospital | 1 | 2008 | 1900 | 0.140 |
Why?
|
| Follow-Up Studies | 10 | 2019 | 4874 | 0.130 |
Why?
|
| Methemoglobin | 2 | 1993 | 20 | 0.130 |
Why?
|
| Smoke Inhalation Injury | 3 | 1991 | 23 | 0.130 |
Why?
|
| Dyspnea | 1 | 2018 | 239 | 0.130 |
Why?
|
| Pulmonary Edema | 1 | 1997 | 104 | 0.130 |
Why?
|
| Blood Circulation | 3 | 1998 | 40 | 0.130 |
Why?
|
| Anesthesia, Local | 1 | 2016 | 15 | 0.130 |
Why?
|
| Capillary Permeability | 1 | 1997 | 131 | 0.130 |
Why?
|
| Glycocalyx | 1 | 2016 | 19 | 0.130 |
Why?
|
| Antiemetics | 1 | 1997 | 40 | 0.130 |
Why?
|
| Estradiol | 4 | 2001 | 489 | 0.130 |
Why?
|
| Mentors | 1 | 2018 | 178 | 0.130 |
Why?
|
| Child, Preschool | 14 | 2017 | 10487 | 0.130 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 260 | 0.130 |
Why?
|
| Cardiac Catheterization | 6 | 2022 | 517 | 0.130 |
Why?
|
| Infant, Newborn, Diseases | 2 | 2014 | 109 | 0.130 |
Why?
|
| Survivors | 1 | 2019 | 462 | 0.130 |
Why?
|
| Echocardiography, Doppler | 2 | 2001 | 108 | 0.130 |
Why?
|
| Disease Management | 2 | 2017 | 584 | 0.130 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 1996 | 14 | 0.130 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2019 | 228 | 0.130 |
Why?
|
| Hypnotics and Sedatives | 2 | 2024 | 157 | 0.130 |
Why?
|
| Dimensional Measurement Accuracy | 1 | 2015 | 13 | 0.130 |
Why?
|
| Down Syndrome | 1 | 2022 | 471 | 0.130 |
Why?
|
| Length of Stay | 5 | 2017 | 1119 | 0.120 |
Why?
|
| Surgical Procedures, Operative | 1 | 2018 | 243 | 0.120 |
Why?
|
| Nitroarginine | 10 | 2005 | 57 | 0.120 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2016 | 35 | 0.120 |
Why?
|
| Chronic Disease | 8 | 2013 | 1692 | 0.120 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 712 | 0.120 |
Why?
|
| Neutrophils | 3 | 1999 | 1192 | 0.120 |
Why?
|
| Prognosis | 6 | 2023 | 3780 | 0.120 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 480 | 0.120 |
Why?
|
| Cerebrovascular Circulation | 3 | 1995 | 217 | 0.120 |
Why?
|
| Radiography | 2 | 2008 | 795 | 0.120 |
Why?
|
| Faculty, Medical | 1 | 2018 | 263 | 0.120 |
Why?
|
| Middle Aged | 15 | 2019 | 30923 | 0.120 |
Why?
|
| Risk Assessment | 4 | 2017 | 3232 | 0.120 |
Why?
|
| United Kingdom | 2 | 2013 | 258 | 0.120 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 302 | 0.120 |
Why?
|
| Sildenafil Citrate | 4 | 2021 | 59 | 0.120 |
Why?
|
| Statistics as Topic | 1 | 2015 | 304 | 0.120 |
Why?
|
| Logistic Models | 4 | 2024 | 1980 | 0.110 |
Why?
|
| Double-Blind Method | 3 | 2009 | 1856 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2011 | 503 | 0.110 |
Why?
|
| Ventilator Weaning | 2 | 2005 | 37 | 0.110 |
Why?
|
| Mothers | 1 | 2020 | 729 | 0.110 |
Why?
|
| Registries | 5 | 2022 | 1883 | 0.110 |
Why?
|
| Ammonia | 2 | 1992 | 62 | 0.110 |
Why?
|
| Thrombosis | 1 | 2017 | 343 | 0.110 |
Why?
|
| Pediatrics | 2 | 2019 | 1050 | 0.110 |
Why?
|
| Biomarkers | 4 | 2016 | 3893 | 0.110 |
Why?
|
| Vasopressins | 1 | 2014 | 64 | 0.110 |
Why?
|
| Continuity of Patient Care | 1 | 2016 | 275 | 0.110 |
Why?
|
| Aged | 12 | 2019 | 21976 | 0.110 |
Why?
|
| Vasoconstrictor Agents | 1 | 2014 | 127 | 0.110 |
Why?
|
| Clinical Trials as Topic | 3 | 2008 | 1003 | 0.110 |
Why?
|
| Elective Surgical Procedures | 2 | 2011 | 163 | 0.110 |
Why?
|
| Survival Analysis | 3 | 2009 | 1265 | 0.110 |
Why?
|
| Alcohol Withdrawal Delirium | 1 | 2013 | 7 | 0.110 |
Why?
|
| Pilot Projects | 5 | 2024 | 1568 | 0.100 |
Why?
|
| Hemorrhage | 1 | 2017 | 666 | 0.100 |
Why?
|
| Hypotension | 1 | 2014 | 115 | 0.100 |
Why?
|
| Epoprostenol | 3 | 2021 | 134 | 0.100 |
Why?
|
| Cell Nucleus | 1 | 1996 | 580 | 0.100 |
Why?
|
| Cyclic GMP | 4 | 2001 | 85 | 0.100 |
Why?
|
| Coronary Circulation | 2 | 1995 | 137 | 0.100 |
Why?
|
| Critical Care Nursing | 1 | 2013 | 36 | 0.100 |
Why?
|
| Diaphragm | 2 | 2023 | 43 | 0.100 |
Why?
|
| Renal Dialysis | 1 | 2016 | 423 | 0.100 |
Why?
|
| Pain, Postoperative | 2 | 2024 | 222 | 0.100 |
Why?
|
| Adult | 15 | 2024 | 35302 | 0.100 |
Why?
|
| Vascular Diseases | 1 | 2015 | 232 | 0.100 |
Why?
|
| Liver Cirrhosis | 1 | 2014 | 279 | 0.100 |
Why?
|
| Early Diagnosis | 1 | 2013 | 234 | 0.090 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2011 | 8 | 0.090 |
Why?
|
| Recombinant Proteins | 2 | 2024 | 1291 | 0.090 |
Why?
|
| Delivery Rooms | 1 | 2011 | 7 | 0.090 |
Why?
|
| Ventilators, Mechanical | 2 | 2016 | 53 | 0.090 |
Why?
|
| Troponin | 1 | 2011 | 50 | 0.090 |
Why?
|
| Patient Admission | 1 | 2013 | 182 | 0.090 |
Why?
|
| Kidney Tubules | 1 | 1992 | 114 | 0.090 |
Why?
|
| Acetylcholine | 5 | 2001 | 181 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2018 | 3339 | 0.090 |
Why?
|
| Respiratory Mechanics | 3 | 1999 | 63 | 0.090 |
Why?
|
| Diseases in Twins | 1 | 2012 | 176 | 0.090 |
Why?
|
| Cardiac Output, Low | 1 | 1991 | 66 | 0.090 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2012 | 179 | 0.090 |
Why?
|
| Monitoring, Intraoperative | 2 | 2008 | 44 | 0.090 |
Why?
|
| Alfentanil | 1 | 2010 | 2 | 0.090 |
Why?
|
| Delivery, Obstetric | 1 | 1991 | 137 | 0.090 |
Why?
|
| Oocyte Retrieval | 1 | 2010 | 12 | 0.090 |
Why?
|
| Disease Models, Animal | 7 | 2007 | 3947 | 0.090 |
Why?
|
| Nitric Oxide Synthase Type III | 7 | 2007 | 197 | 0.090 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2011 | 154 | 0.090 |
Why?
|
| Vitamin D Deficiency | 1 | 2012 | 176 | 0.090 |
Why?
|
| Communication | 1 | 2016 | 841 | 0.090 |
Why?
|
| DNA-Binding Proteins | 2 | 2007 | 1423 | 0.090 |
Why?
|
| Endothelium, Vascular | 5 | 2016 | 844 | 0.080 |
Why?
|
| Thermodilution | 2 | 2005 | 13 | 0.080 |
Why?
|
| Physicians | 1 | 2018 | 863 | 0.080 |
Why?
|
| Platelet-Derived Growth Factor | 2 | 2003 | 88 | 0.080 |
Why?
|
| Abdomen | 1 | 2010 | 118 | 0.080 |
Why?
|
| Positive-Pressure Respiration | 2 | 2000 | 75 | 0.080 |
Why?
|
| Airway Obstruction | 1 | 1991 | 149 | 0.080 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2010 | 69 | 0.080 |
Why?
|
| Analysis of Variance | 6 | 2014 | 1273 | 0.080 |
Why?
|
| Endothelin Receptor Antagonists | 3 | 1998 | 61 | 0.080 |
Why?
|
| Endothelins | 3 | 2000 | 59 | 0.080 |
Why?
|
| Cohort Studies | 4 | 2024 | 5402 | 0.080 |
Why?
|
| Vitamin D | 1 | 2012 | 380 | 0.080 |
Why?
|
| Hospitalization | 1 | 2018 | 2069 | 0.080 |
Why?
|
| Prostaglandins | 2 | 2001 | 85 | 0.080 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2011 | 224 | 0.080 |
Why?
|
| Point-of-Care Systems | 1 | 2010 | 146 | 0.070 |
Why?
|
| Anesthetics, Combined | 1 | 2008 | 7 | 0.070 |
Why?
|
| Patient Readmission | 1 | 2013 | 665 | 0.070 |
Why?
|
| Regional Blood Flow | 4 | 1998 | 458 | 0.070 |
Why?
|
| Chest Wall Oscillation | 1 | 2007 | 4 | 0.070 |
Why?
|
| Transcription Factors | 1 | 1996 | 1635 | 0.070 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2011 | 518 | 0.070 |
Why?
|
| Hydrocortisone | 1 | 2010 | 304 | 0.070 |
Why?
|
| Acute Disease | 2 | 2005 | 965 | 0.070 |
Why?
|
| Receptors, Endothelin | 3 | 2000 | 49 | 0.070 |
Why?
|
| Lung Neoplasms | 2 | 2019 | 2329 | 0.070 |
Why?
|
| Neoplasms | 2 | 2019 | 2463 | 0.070 |
Why?
|
| Sex Distribution | 1 | 2008 | 358 | 0.070 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 2 | 1998 | 17 | 0.070 |
Why?
|
| Microspheres | 3 | 1991 | 125 | 0.070 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2004 | 89 | 0.070 |
Why?
|
| Leukomalacia, Periventricular | 1 | 2006 | 7 | 0.070 |
Why?
|
| Purines | 3 | 2013 | 169 | 0.070 |
Why?
|
| Piperidines | 1 | 2008 | 191 | 0.060 |
Why?
|
| Swine | 2 | 2003 | 742 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2010 | 958 | 0.060 |
Why?
|
| Intracranial Hemorrhages | 1 | 2006 | 80 | 0.060 |
Why?
|
| Endothelin-1 | 5 | 2000 | 175 | 0.060 |
Why?
|
| Methyl Ethers | 1 | 2005 | 8 | 0.060 |
Why?
|
| Enzyme Inhibitors | 7 | 2005 | 813 | 0.060 |
Why?
|
| Cross-Over Studies | 2 | 1998 | 509 | 0.060 |
Why?
|
| Atrial Natriuretic Factor | 2 | 1996 | 56 | 0.060 |
Why?
|
| Electroencephalography | 1 | 2008 | 396 | 0.060 |
Why?
|
| Anesthetics, Inhalation | 1 | 2005 | 16 | 0.060 |
Why?
|
| Lung Compliance | 1 | 2005 | 45 | 0.060 |
Why?
|
| Signal Transduction | 3 | 2005 | 4825 | 0.060 |
Why?
|
| Airway Resistance | 1 | 2005 | 38 | 0.060 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 1 | 2005 | 39 | 0.060 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 258 | 0.060 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2007 | 231 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2006 | 2710 | 0.060 |
Why?
|
| Prenatal Care | 1 | 2007 | 275 | 0.060 |
Why?
|
| Aging | 2 | 1992 | 1755 | 0.060 |
Why?
|
| Electric Impedance | 1 | 2005 | 101 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 1938 | 0.060 |
Why?
|
| Pulmonary Wedge Pressure | 2 | 2022 | 66 | 0.060 |
Why?
|
| Amides | 1 | 2005 | 90 | 0.060 |
Why?
|
| Drug Administration Schedule | 4 | 2011 | 764 | 0.060 |
Why?
|
| Rats | 7 | 2005 | 5246 | 0.060 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2013 | 1262 | 0.060 |
Why?
|
| Carbon Dioxide | 4 | 1999 | 258 | 0.050 |
Why?
|
| Carcinoma | 2 | 2016 | 215 | 0.050 |
Why?
|
| Home Nursing | 1 | 2003 | 26 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 3 | 2011 | 569 | 0.050 |
Why?
|
| Coronary Artery Bypass | 1 | 2005 | 222 | 0.050 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2003 | 89 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2010 | 751 | 0.050 |
Why?
|
| Esophagus | 1 | 2005 | 248 | 0.050 |
Why?
|
| Birth Weight | 1 | 2006 | 499 | 0.050 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 51 | 0.050 |
Why?
|
| Analgesics | 1 | 2024 | 166 | 0.050 |
Why?
|
| Lymphokines | 1 | 2002 | 115 | 0.050 |
Why?
|
| Disability Evaluation | 1 | 2024 | 285 | 0.050 |
Why?
|
| Embryonic and Fetal Development | 3 | 2000 | 92 | 0.050 |
Why?
|
| Forced Expiratory Volume | 2 | 2016 | 511 | 0.050 |
Why?
|
| Intermittent Positive-Pressure Ventilation | 2 | 1993 | 11 | 0.050 |
Why?
|
| Surgical Flaps | 1 | 2023 | 135 | 0.050 |
Why?
|
| Stomach | 1 | 2002 | 109 | 0.050 |
Why?
|
| Mouth Mucosa | 1 | 2022 | 89 | 0.050 |
Why?
|
| Sequence Deletion | 1 | 2022 | 178 | 0.050 |
Why?
|
| Mosaicism | 1 | 2022 | 71 | 0.050 |
Why?
|
| Thyroid Neoplasms | 2 | 2016 | 309 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 5045 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 2 | 1992 | 171 | 0.050 |
Why?
|
| Forkhead Transcription Factors | 1 | 2022 | 181 | 0.050 |
Why?
|
| Phenotype | 2 | 2023 | 3051 | 0.050 |
Why?
|
| APACHE | 1 | 2001 | 65 | 0.050 |
Why?
|
| Estrogen Antagonists | 1 | 2001 | 45 | 0.050 |
Why?
|
| Uterus | 1 | 2002 | 206 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2002 | 372 | 0.040 |
Why?
|
| Muscle, Smooth | 2 | 2000 | 152 | 0.040 |
Why?
|
| Milrinone | 1 | 2021 | 29 | 0.040 |
Why?
|
| Labor, Obstetric | 1 | 2001 | 58 | 0.040 |
Why?
|
| Ligation | 5 | 2002 | 86 | 0.040 |
Why?
|
| Calibration | 1 | 2001 | 135 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 5371 | 0.040 |
Why?
|
| Injections, Intra-Arterial | 1 | 2000 | 24 | 0.040 |
Why?
|
| Protoporphyrins | 1 | 2000 | 16 | 0.040 |
Why?
|
| Self Report | 1 | 2024 | 797 | 0.040 |
Why?
|
| Inflammation | 1 | 2010 | 2666 | 0.040 |
Why?
|
| Patient Transfer | 1 | 2002 | 162 | 0.040 |
Why?
|
| Hydrocarbons, Brominated | 1 | 1999 | 4 | 0.040 |
Why?
|
| Adolescent | 8 | 2005 | 20304 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2019 | 108 | 0.040 |
Why?
|
| Postoperative Period | 2 | 2016 | 324 | 0.040 |
Why?
|
| Blotting, Northern | 4 | 2000 | 198 | 0.040 |
Why?
|
| Potassium Channel Blockers | 1 | 1999 | 34 | 0.040 |
Why?
|
| Esophageal Neoplasms | 1 | 2002 | 293 | 0.040 |
Why?
|
| Scotland | 1 | 2018 | 12 | 0.040 |
Why?
|
| Angiography | 1 | 1999 | 192 | 0.040 |
Why?
|
| Constriction, Pathologic | 1 | 1999 | 228 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2001 | 425 | 0.040 |
Why?
|
| Digestive System Physiological Phenomena | 1 | 1998 | 4 | 0.040 |
Why?
|
| Acidosis | 2 | 1992 | 88 | 0.040 |
Why?
|
| Drug Synergism | 2 | 1998 | 357 | 0.040 |
Why?
|
| Leukocyte Count | 2 | 1997 | 326 | 0.040 |
Why?
|
| Asphyxia Neonatorum | 1 | 1998 | 18 | 0.040 |
Why?
|
| Blood Vessels | 1 | 2000 | 183 | 0.040 |
Why?
|
| Body Weight | 2 | 2005 | 933 | 0.040 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 1998 | 47 | 0.040 |
Why?
|
| Immunohistochemistry | 4 | 2005 | 1668 | 0.040 |
Why?
|
| Frontal Bone | 1 | 1997 | 12 | 0.040 |
Why?
|
| Occipital Bone | 1 | 1997 | 18 | 0.040 |
Why?
|
| Receptor, Endothelin A | 4 | 2000 | 62 | 0.040 |
Why?
|
| Disease Progression | 2 | 2017 | 2604 | 0.040 |
Why?
|
| Cephalometry | 1 | 1997 | 31 | 0.040 |
Why?
|
| Potassium Channels | 1 | 1998 | 144 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2002 | 622 | 0.030 |
Why?
|
| Growth | 1 | 1997 | 58 | 0.030 |
Why?
|
| Arterial Pressure | 1 | 2017 | 117 | 0.030 |
Why?
|
| Syndecan-1 | 1 | 2016 | 27 | 0.030 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 2016 | 21 | 0.030 |
Why?
|
| Blood Pressure Determination | 1 | 2017 | 148 | 0.030 |
Why?
|
| Molecular Sequence Data | 3 | 1998 | 2822 | 0.030 |
Why?
|
| Kidney | 3 | 1991 | 1310 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1997 | 168 | 0.030 |
Why?
|
| Ventricular Function, Right | 1 | 2019 | 275 | 0.030 |
Why?
|
| Expectorants | 1 | 2016 | 24 | 0.030 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2016 | 16 | 0.030 |
Why?
|
| Patient Selection | 1 | 2000 | 661 | 0.030 |
Why?
|
| Nausea | 1 | 1997 | 108 | 0.030 |
Why?
|
| Body Height | 1 | 1997 | 193 | 0.030 |
Why?
|
| Endothelin-3 | 1 | 1996 | 3 | 0.030 |
Why?
|
| Vascular Patency | 1 | 2016 | 102 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2017 | 254 | 0.030 |
Why?
|
| Ireland | 1 | 2016 | 27 | 0.030 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2016 | 53 | 0.030 |
Why?
|
| Interferon-Stimulated Gene Factor 3 | 1 | 1996 | 1 | 0.030 |
Why?
|
| Arginine | 2 | 1994 | 260 | 0.030 |
Why?
|
| Rats, Inbred Strains | 3 | 1992 | 362 | 0.030 |
Why?
|
| Gastrostomy | 1 | 1997 | 110 | 0.030 |
Why?
|
| Vomiting | 1 | 1997 | 126 | 0.030 |
Why?
|
| Arteriovenous Fistula | 1 | 2016 | 35 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 1996 | 34 | 0.030 |
Why?
|
| Lung Injury | 2 | 2011 | 199 | 0.030 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1998 | 172 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2019 | 589 | 0.030 |
Why?
|
| Algorithms | 2 | 2000 | 1614 | 0.030 |
Why?
|
| Luciferases | 1 | 1996 | 147 | 0.030 |
Why?
|
| Steroids | 1 | 2016 | 147 | 0.030 |
Why?
|
| Enteral Nutrition | 1 | 1997 | 186 | 0.030 |
Why?
|
| Blotting, Western | 3 | 2005 | 1170 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 1999 | 1412 | 0.030 |
Why?
|
| Genetic Counseling | 1 | 2015 | 72 | 0.030 |
Why?
|
| Age Factors | 2 | 2000 | 3122 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 1996 | 266 | 0.030 |
Why?
|
| Tyrosine | 1 | 1996 | 218 | 0.030 |
Why?
|
| Indiana | 1 | 2015 | 33 | 0.030 |
Why?
|
| Ventilator-Induced Lung Injury | 1 | 2015 | 56 | 0.030 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2001 | 564 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type II | 3 | 2001 | 169 | 0.030 |
Why?
|
| Peptides, Cyclic | 4 | 1998 | 255 | 0.030 |
Why?
|
| Biological Transport | 3 | 1991 | 396 | 0.030 |
Why?
|
| Aorta | 4 | 1998 | 408 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2016 | 188 | 0.030 |
Why?
|
| Psychomotor Performance | 1 | 1997 | 312 | 0.030 |
Why?
|
| Endothelium | 1 | 1995 | 107 | 0.030 |
Why?
|
| Base Sequence | 2 | 1996 | 2137 | 0.030 |
Why?
|
| Organ Dysfunction Scores | 1 | 2014 | 44 | 0.030 |
Why?
|
| Infant, Low Birth Weight | 1 | 2015 | 135 | 0.030 |
Why?
|
| Cardiovascular Agents | 1 | 2015 | 152 | 0.030 |
Why?
|
| Costs and Cost Analysis | 2 | 2009 | 200 | 0.030 |
Why?
|
| Vasomotor System | 3 | 2002 | 43 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 1996 | 356 | 0.030 |
Why?
|
| Life Support Care | 1 | 2014 | 29 | 0.030 |
Why?
|
| Schools, Medical | 1 | 2015 | 130 | 0.030 |
Why?
|
| Blood Flow Velocity | 2 | 1992 | 404 | 0.030 |
Why?
|
| Stress, Mechanical | 3 | 2001 | 463 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 293 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 1993 | 80 | 0.030 |
Why?
|
| Acute Lung Injury | 1 | 2016 | 264 | 0.030 |
Why?
|
| Young Adult | 1 | 2009 | 12349 | 0.030 |
Why?
|
| In Vitro Techniques | 2 | 1992 | 1047 | 0.030 |
Why?
|
| Reference Values | 3 | 2002 | 780 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1996 | 636 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 1997 | 482 | 0.030 |
Why?
|
| Prevalence | 1 | 2019 | 2553 | 0.030 |
Why?
|
| United States | 3 | 2012 | 13840 | 0.030 |
Why?
|
| Lung Transplantation | 1 | 2015 | 278 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 332 | 0.030 |
Why?
|
| DNA | 2 | 1998 | 1394 | 0.030 |
Why?
|
| Hypertension | 1 | 2002 | 1236 | 0.030 |
Why?
|
| ROC Curve | 1 | 2014 | 502 | 0.030 |
Why?
|
| Decision Making | 1 | 2019 | 847 | 0.030 |
Why?
|
| Lactic Acid | 1 | 2014 | 294 | 0.030 |
Why?
|
| Child Development | 1 | 1997 | 455 | 0.020 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2012 | 61 | 0.020 |
Why?
|
| Ammonium Chloride | 1 | 1992 | 5 | 0.020 |
Why?
|
| Brain Chemistry | 1 | 1992 | 115 | 0.020 |
Why?
|
| Nephrons | 1 | 1992 | 17 | 0.020 |
Why?
|
| Streptococcus agalactiae | 1 | 1993 | 93 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 7057 | 0.020 |
Why?
|
| Brain | 2 | 1997 | 2624 | 0.020 |
Why?
|
| Liver | 1 | 2020 | 1827 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 1995 | 327 | 0.020 |
Why?
|
| Isotonic Solutions | 1 | 2011 | 37 | 0.020 |
Why?
|
| Asthma | 1 | 2005 | 2213 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2012 | 198 | 0.020 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2001 | 73 | 0.020 |
Why?
|
| Fetal Diseases | 2 | 2003 | 156 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2014 | 1019 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2012 | 190 | 0.020 |
Why?
|
| Streptococcal Infections | 1 | 1993 | 147 | 0.020 |
Why?
|
| Carboxyhemoglobin | 1 | 1991 | 5 | 0.020 |
Why?
|
| Radioisotopes | 1 | 1991 | 31 | 0.020 |
Why?
|
| Phosphorylation | 1 | 1996 | 1686 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 1996 | 1199 | 0.020 |
Why?
|
| Body Constitution | 1 | 1991 | 53 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2015 | 712 | 0.020 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 1993 | 203 | 0.020 |
Why?
|
| RNA, Messenger | 3 | 2007 | 2679 | 0.020 |
Why?
|
| Hypertrophy, Right Ventricular | 2 | 2003 | 134 | 0.020 |
Why?
|
| Models, Cardiovascular | 1 | 1992 | 190 | 0.020 |
Why?
|
| Echovirus Infections | 1 | 1990 | 1 | 0.020 |
Why?
|
| Burns | 2 | 1991 | 284 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2010 | 113 | 0.020 |
Why?
|
| Enterovirus B, Human | 1 | 1990 | 25 | 0.020 |
Why?
|
| Meningoencephalitis | 1 | 1990 | 25 | 0.020 |
Why?
|
| Medical Audit | 1 | 2010 | 77 | 0.020 |
Why?
|
| Guanidines | 2 | 2001 | 36 | 0.020 |
Why?
|
| Isoenzymes | 2 | 2001 | 302 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 2009 | 115 | 0.020 |
Why?
|
| Hospital Costs | 1 | 2010 | 114 | 0.020 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2001 | 80 | 0.020 |
Why?
|
| Tetraethylammonium | 2 | 1999 | 17 | 0.020 |
Why?
|
| 4-Aminopyridine | 2 | 1999 | 23 | 0.020 |
Why?
|
| Pressure | 2 | 2002 | 237 | 0.020 |
Why?
|
| Macrophages, Alveolar | 1 | 1991 | 375 | 0.020 |
Why?
|
| Constriction | 2 | 1999 | 42 | 0.020 |
Why?
|
| Heart Diseases | 1 | 1992 | 347 | 0.020 |
Why?
|
| Immunologic Techniques | 2 | 1999 | 38 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 1996 | 4017 | 0.020 |
Why?
|
| Cardiography, Impedance | 1 | 2007 | 8 | 0.020 |
Why?
|
| Organ Size | 2 | 2005 | 441 | 0.020 |
Why?
|
| Receptor, Endothelin B | 2 | 2000 | 50 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2010 | 982 | 0.020 |
Why?
|
| Heart Rate, Fetal | 2 | 1999 | 20 | 0.020 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2007 | 21 | 0.020 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1990 | 624 | 0.020 |
Why?
|
| Immediate-Early Proteins | 1 | 2007 | 51 | 0.020 |
Why?
|
| Protein Precursors | 2 | 2000 | 127 | 0.020 |
Why?
|
| Developmental Disabilities | 1 | 2009 | 259 | 0.020 |
Why?
|
| Acute Kidney Injury | 1 | 2014 | 779 | 0.020 |
Why?
|
| RNA, Viral | 1 | 1990 | 615 | 0.020 |
Why?
|
| Proteins | 1 | 1992 | 936 | 0.020 |
Why?
|
| Comorbidity | 1 | 2010 | 1541 | 0.020 |
Why?
|
| Thoracic Diseases | 1 | 2005 | 14 | 0.020 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 1987 | 175 | 0.020 |
Why?
|
| Respiratory Muscles | 1 | 2005 | 32 | 0.020 |
Why?
|
| Oscillometry | 1 | 2005 | 37 | 0.010 |
Why?
|
| Phosphates | 1 | 1986 | 169 | 0.010 |
Why?
|
| Manometry | 1 | 2005 | 90 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2005 | 81 | 0.010 |
Why?
|
| Hypertrophy | 1 | 2005 | 115 | 0.010 |
Why?
|
| Colorado | 1 | 2015 | 4399 | 0.010 |
Why?
|
| Muscular Diseases | 1 | 2005 | 107 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2005 | 324 | 0.010 |
Why?
|
| Pulse Therapy, Drug | 1 | 2003 | 7 | 0.010 |
Why?
|
| Research Design | 1 | 2010 | 1036 | 0.010 |
Why?
|
| Time | 1 | 2003 | 75 | 0.010 |
Why?
|
| Administration, Intranasal | 1 | 2003 | 83 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2007 | 489 | 0.010 |
Why?
|
| Pyrroles | 1 | 2004 | 190 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 941 | 0.010 |
Why?
|
| Pharyngectomy | 1 | 2002 | 3 | 0.010 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2002 | 3 | 0.010 |
Why?
|
| Speech, Alaryngeal | 1 | 2002 | 3 | 0.010 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2003 | 29 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2010 | 1009 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2002 | 65 | 0.010 |
Why?
|
| Laryngectomy | 1 | 2002 | 14 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1987 | 732 | 0.010 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2003 | 45 | 0.010 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2002 | 77 | 0.010 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2002 | 54 | 0.010 |
Why?
|
| Nifedipine | 1 | 2002 | 28 | 0.010 |
Why?
|
| Meclofenamic Acid | 1 | 2001 | 10 | 0.010 |
Why?
|
| 8-Bromo Cyclic Adenosine Monophosphate | 1 | 2001 | 20 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2005 | 608 | 0.010 |
Why?
|
| Oligonucleotides | 1 | 2002 | 139 | 0.010 |
Why?
|
| Cyclooxygenase 1 | 1 | 2001 | 26 | 0.010 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2001 | 54 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 419 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 1986 | 573 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 2002 | 164 | 0.010 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2001 | 62 | 0.010 |
Why?
|
| Amidines | 1 | 2001 | 16 | 0.010 |
Why?
|
| Calcium Channel Blockers | 1 | 2002 | 124 | 0.010 |
Why?
|
| Esophagectomy | 1 | 2002 | 124 | 0.010 |
Why?
|
| Benzylamines | 1 | 2001 | 41 | 0.010 |
Why?
|
| Indoles | 1 | 2004 | 372 | 0.010 |
Why?
|
| Pulmonary Ventilation | 1 | 2001 | 77 | 0.010 |
Why?
|
| Calcium Channels | 1 | 2002 | 152 | 0.010 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2001 | 127 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2001 | 290 | 0.010 |
Why?
|
| Ligands | 1 | 2003 | 617 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2001 | 178 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2001 | 361 | 0.010 |
Why?
|
| Calcium | 1 | 1986 | 1183 | 0.010 |
Why?
|
| Physical Stimulation | 1 | 2000 | 74 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2005 | 2272 | 0.010 |
Why?
|
| Lung Volume Measurements | 1 | 1999 | 43 | 0.010 |
Why?
|
| Charybdotoxin | 1 | 1999 | 6 | 0.010 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2005 | 592 | 0.010 |
Why?
|
| Atrial Function, Right | 1 | 1998 | 12 | 0.010 |
Why?
|
| Delayed Rectifier Potassium Channels | 1 | 1998 | 9 | 0.010 |
Why?
|
| Shab Potassium Channels | 1 | 1998 | 18 | 0.010 |
Why?
|
| Digestive System | 1 | 1998 | 29 | 0.010 |
Why?
|
| Electric Conductivity | 1 | 1998 | 94 | 0.010 |
Why?
|
| Isothiuronium | 1 | 1998 | 3 | 0.010 |
Why?
|
| Xenopus | 1 | 1998 | 85 | 0.010 |
Why?
|
| Thiazines | 1 | 1998 | 9 | 0.010 |
Why?
|
| Long-Term Care | 1 | 1998 | 91 | 0.010 |
Why?
|
| Masks | 1 | 1998 | 59 | 0.010 |
Why?
|
| Quality of Life | 1 | 2009 | 2688 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2002 | 819 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1998 | 267 | 0.010 |
Why?
|
| Catheterization | 1 | 1998 | 173 | 0.010 |
Why?
|
| Gene Expression | 1 | 2003 | 1455 | 0.010 |
Why?
|
| Medical Records | 1 | 1998 | 170 | 0.010 |
Why?
|
| Oocytes | 1 | 1998 | 174 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1998 | 522 | 0.010 |
Why?
|
| Dogs | 1 | 1998 | 368 | 0.010 |
Why?
|
| Methylene Blue | 1 | 1996 | 23 | 0.010 |
Why?
|
| Indomethacin | 1 | 1996 | 77 | 0.010 |
Why?
|
| Microvilli | 2 | 1987 | 77 | 0.010 |
Why?
|
| Adenosine | 1 | 1998 | 212 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1996 | 137 | 0.010 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 1995 | 8 | 0.010 |
Why?
|
| Cardiomegaly | 1 | 1997 | 168 | 0.010 |
Why?
|
| Purinones | 1 | 1995 | 4 | 0.010 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 1995 | 8 | 0.010 |
Why?
|
| Receptors, Purinergic P1 | 1 | 1995 | 23 | 0.010 |
Why?
|
| Sodium | 2 | 1987 | 202 | 0.010 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 1995 | 34 | 0.010 |
Why?
|
| Arterioles | 1 | 1995 | 41 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 1999 | 1499 | 0.010 |
Why?
|
| Theophylline | 1 | 1995 | 64 | 0.010 |
Why?
|
| Carcinoma, Papillary | 1 | 1995 | 76 | 0.010 |
Why?
|
| Home Care Services | 1 | 1998 | 244 | 0.010 |
Why?
|
| Neurotransmitter Agents | 1 | 1995 | 78 | 0.010 |
Why?
|
| Phenylephrine | 1 | 1995 | 74 | 0.010 |
Why?
|
| Renal Circulation | 1 | 1995 | 57 | 0.010 |
Why?
|
| Adrenal Glands | 1 | 1995 | 70 | 0.010 |
Why?
|
| Viper Venoms | 1 | 1994 | 9 | 0.010 |
Why?
|
| Muscle Tonus | 1 | 1994 | 20 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1998 | 2044 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 1995 | 478 | 0.010 |
Why?
|
| Forecasting | 1 | 1995 | 356 | 0.010 |
Why?
|
| Cause of Death | 1 | 1995 | 392 | 0.010 |
Why?
|
| Perfusion | 1 | 1994 | 188 | 0.010 |
Why?
|
| Intestines | 1 | 1995 | 344 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 1995 | 499 | 0.010 |
Why?
|
| Chemotaxis | 1 | 1991 | 128 | 0.010 |
Why?
|
| Macrophage Activation | 1 | 1991 | 187 | 0.010 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1990 | 26 | 0.010 |
Why?
|
| Agammaglobulinemia | 1 | 1990 | 33 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1990 | 188 | 0.010 |
Why?
|
| Gene Amplification | 1 | 1990 | 104 | 0.010 |
Why?
|
| Cell Count | 1 | 1990 | 310 | 0.000 |
Why?
|
| Myocardial Contraction | 1 | 1990 | 334 | 0.000 |
Why?
|
| Adenocarcinoma | 1 | 1995 | 894 | 0.000 |
Why?
|
| Eosinophils | 1 | 1990 | 323 | 0.000 |
Why?
|
| Kidney Cortex | 1 | 1987 | 25 | 0.000 |
Why?
|
| Sodium-Hydrogen Exchangers | 1 | 1987 | 26 | 0.000 |
Why?
|
| Polymerase Chain Reaction | 1 | 1990 | 1027 | 0.000 |
Why?
|
| Monocytes | 1 | 1990 | 546 | 0.000 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1987 | 541 | 0.000 |
Why?
|
| Skin | 1 | 1990 | 717 | 0.000 |
Why?
|
| Glomerular Filtration Rate | 1 | 1987 | 684 | 0.000 |
Why?
|
| Macrophages | 1 | 1990 | 1464 | 0.000 |
Why?
|